Abnormal p53 expression in lung neuroendocrine tumors: Diagnostic and prognostic implications

Massimo Roncalli, Claudio Doglioni, David R. Springall, Mauro Papotti, Alberto Pagani, Julia M. Polak, Nassif B N Ibrahim, Guido Coggi, Giuseppe Viale

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The diagnostic and prognostic implications of p53 immunostaining have been investigated in 59 pulmonary neuroendocrine tumors, including typical carcinoids (n = 15), so-called “atypical carcinoids” (n = 22), and small cell lung carcinomas (SCLCs; n = 22). Immunocyto-chemistry was performed on formalin-fixed, paraffin-embedded samples using the monoclonal antibody PAM801. which has been shown to be suitable for staining fixed and embedded tissue sections. p53 immunore-activity was restricted to atypical carcinoids (45% of the cases being immunoreactive) and to SCLCs (which were positively stained in 59% of the cases), whereas it was consistently lacking in typical carcinoid tumors. When the group of the so-called “atypical carcinoids” was further reclassified, p53 immunostaining was strictly confined to those cases belonging to the histologically more aggressive subsets (well differentiated neuroendocrine carcinoma subsets II and III). Within the same tumor type, however, p53 immunoreactivity did not correlate with the clinical outcome of the disease and was not predictive of the length of survival. The data indicate that abnormal p53 expression (which is strictly dependent on structural abnormalities of the p53 gene) is detectable in the majority of neuroendocrine carcinomas of the lung and might represent a useful adjunct in the differential diagnosis of pulmonary neuroendocrine neoplasms, particularly in routinely fixed and embedded small bronchoscopic biopsies.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalDiagnostic Molecular Pathology
Volume1
Issue number2
Publication statusPublished - 1992

Fingerprint

Neuroendocrine Tumors
Carcinoid Tumor
Lung
Neuroendocrine Carcinoma
p53 Genes
Small Cell Lung Carcinoma
Paraffin
Formaldehyde
Lung Neoplasms
Differential Diagnosis
Monoclonal Antibodies
Staining and Labeling
Biopsy
Neoplasms

Keywords

  • Abnormal p53 expression
  • Lung neuroendocrine tumors
  • Proliferating cell nuclear antigen

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this

Abnormal p53 expression in lung neuroendocrine tumors : Diagnostic and prognostic implications. / Roncalli, Massimo; Doglioni, Claudio; Springall, David R.; Papotti, Mauro; Pagani, Alberto; Polak, Julia M.; Ibrahim, Nassif B N; Coggi, Guido; Viale, Giuseppe.

In: Diagnostic Molecular Pathology, Vol. 1, No. 2, 1992, p. 129-135.

Research output: Contribution to journalArticle

Roncalli, M, Doglioni, C, Springall, DR, Papotti, M, Pagani, A, Polak, JM, Ibrahim, NBN, Coggi, G & Viale, G 1992, 'Abnormal p53 expression in lung neuroendocrine tumors: Diagnostic and prognostic implications', Diagnostic Molecular Pathology, vol. 1, no. 2, pp. 129-135.
Roncalli, Massimo ; Doglioni, Claudio ; Springall, David R. ; Papotti, Mauro ; Pagani, Alberto ; Polak, Julia M. ; Ibrahim, Nassif B N ; Coggi, Guido ; Viale, Giuseppe. / Abnormal p53 expression in lung neuroendocrine tumors : Diagnostic and prognostic implications. In: Diagnostic Molecular Pathology. 1992 ; Vol. 1, No. 2. pp. 129-135.
@article{c05701d91bb84c5a84bf29318ae905d4,
title = "Abnormal p53 expression in lung neuroendocrine tumors: Diagnostic and prognostic implications",
abstract = "The diagnostic and prognostic implications of p53 immunostaining have been investigated in 59 pulmonary neuroendocrine tumors, including typical carcinoids (n = 15), so-called “atypical carcinoids” (n = 22), and small cell lung carcinomas (SCLCs; n = 22). Immunocyto-chemistry was performed on formalin-fixed, paraffin-embedded samples using the monoclonal antibody PAM801. which has been shown to be suitable for staining fixed and embedded tissue sections. p53 immunore-activity was restricted to atypical carcinoids (45{\%} of the cases being immunoreactive) and to SCLCs (which were positively stained in 59{\%} of the cases), whereas it was consistently lacking in typical carcinoid tumors. When the group of the so-called “atypical carcinoids” was further reclassified, p53 immunostaining was strictly confined to those cases belonging to the histologically more aggressive subsets (well differentiated neuroendocrine carcinoma subsets II and III). Within the same tumor type, however, p53 immunoreactivity did not correlate with the clinical outcome of the disease and was not predictive of the length of survival. The data indicate that abnormal p53 expression (which is strictly dependent on structural abnormalities of the p53 gene) is detectable in the majority of neuroendocrine carcinomas of the lung and might represent a useful adjunct in the differential diagnosis of pulmonary neuroendocrine neoplasms, particularly in routinely fixed and embedded small bronchoscopic biopsies.",
keywords = "Abnormal p53 expression, Lung neuroendocrine tumors, Proliferating cell nuclear antigen",
author = "Massimo Roncalli and Claudio Doglioni and Springall, {David R.} and Mauro Papotti and Alberto Pagani and Polak, {Julia M.} and Ibrahim, {Nassif B N} and Guido Coggi and Giuseppe Viale",
year = "1992",
language = "English",
volume = "1",
pages = "129--135",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Abnormal p53 expression in lung neuroendocrine tumors

T2 - Diagnostic and prognostic implications

AU - Roncalli, Massimo

AU - Doglioni, Claudio

AU - Springall, David R.

AU - Papotti, Mauro

AU - Pagani, Alberto

AU - Polak, Julia M.

AU - Ibrahim, Nassif B N

AU - Coggi, Guido

AU - Viale, Giuseppe

PY - 1992

Y1 - 1992

N2 - The diagnostic and prognostic implications of p53 immunostaining have been investigated in 59 pulmonary neuroendocrine tumors, including typical carcinoids (n = 15), so-called “atypical carcinoids” (n = 22), and small cell lung carcinomas (SCLCs; n = 22). Immunocyto-chemistry was performed on formalin-fixed, paraffin-embedded samples using the monoclonal antibody PAM801. which has been shown to be suitable for staining fixed and embedded tissue sections. p53 immunore-activity was restricted to atypical carcinoids (45% of the cases being immunoreactive) and to SCLCs (which were positively stained in 59% of the cases), whereas it was consistently lacking in typical carcinoid tumors. When the group of the so-called “atypical carcinoids” was further reclassified, p53 immunostaining was strictly confined to those cases belonging to the histologically more aggressive subsets (well differentiated neuroendocrine carcinoma subsets II and III). Within the same tumor type, however, p53 immunoreactivity did not correlate with the clinical outcome of the disease and was not predictive of the length of survival. The data indicate that abnormal p53 expression (which is strictly dependent on structural abnormalities of the p53 gene) is detectable in the majority of neuroendocrine carcinomas of the lung and might represent a useful adjunct in the differential diagnosis of pulmonary neuroendocrine neoplasms, particularly in routinely fixed and embedded small bronchoscopic biopsies.

AB - The diagnostic and prognostic implications of p53 immunostaining have been investigated in 59 pulmonary neuroendocrine tumors, including typical carcinoids (n = 15), so-called “atypical carcinoids” (n = 22), and small cell lung carcinomas (SCLCs; n = 22). Immunocyto-chemistry was performed on formalin-fixed, paraffin-embedded samples using the monoclonal antibody PAM801. which has been shown to be suitable for staining fixed and embedded tissue sections. p53 immunore-activity was restricted to atypical carcinoids (45% of the cases being immunoreactive) and to SCLCs (which were positively stained in 59% of the cases), whereas it was consistently lacking in typical carcinoid tumors. When the group of the so-called “atypical carcinoids” was further reclassified, p53 immunostaining was strictly confined to those cases belonging to the histologically more aggressive subsets (well differentiated neuroendocrine carcinoma subsets II and III). Within the same tumor type, however, p53 immunoreactivity did not correlate with the clinical outcome of the disease and was not predictive of the length of survival. The data indicate that abnormal p53 expression (which is strictly dependent on structural abnormalities of the p53 gene) is detectable in the majority of neuroendocrine carcinomas of the lung and might represent a useful adjunct in the differential diagnosis of pulmonary neuroendocrine neoplasms, particularly in routinely fixed and embedded small bronchoscopic biopsies.

KW - Abnormal p53 expression

KW - Lung neuroendocrine tumors

KW - Proliferating cell nuclear antigen

UR - http://www.scopus.com/inward/record.url?scp=0026870131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026870131&partnerID=8YFLogxK

M3 - Article

C2 - 1364172

AN - SCOPUS:0026870131

VL - 1

SP - 129

EP - 135

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 2

ER -